Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 24.242 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 48.485 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 96.97 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

Israel - English - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - tablets - isosorbide mononitrate 40 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks, treatment of congestive heart failure.

Israel - English - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - tablets - isosorbide mononitrate 20 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks. treatment of congestive heart failure.

Israel - English - Ministry of Health

cts chemical industries ltd, israel - selegiline hydrochloride - tablets - selegiline hydrochloride 5 mg - selegiline - selegiline - treatment of parkinson's disease or symptomatic parkinsonism.

Israel - English - Ministry of Health

unipharm ltd, israel - alendronate as sodium - tablets - alendronate as sodium 70 mg - alendronic acid - maxibone is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

Israel - English - Ministry of Health

unipharm ltd, israel - paroxetine as hydrochloride - tablets - paroxetine as hydrochloride 30 mg - paroxetine - treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. treatment of symptoms and prevention of relapse of obsessive compulsive disorder (ocd). treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia.treatment of symptoms of social phobia.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - misoprostol - tablets - misoprostol 200 mcg - misoprostol - misoprostol - for the treatment of duodenal and gastric ulcer.treatment and prevention nsaid induced ulcers lesions, erosions, while nsaid therapy continues.use in conjunction with mifepristone subject to the approval of a committee for the termination of pregnancy according to the israeli penal law 1977.first-trimester pregnancy failure: use is intended for emptying the uterus in states of first trimester pregnancy failure, including: presentation of a pregnancy sac in the uterus with no fetal echo, missed abortion (until week 11+6 and a fetus 40 mm in length) or incomplete abortion. the preparation is to be used after location of the sac in the uterus has been proved and the diagnosis of pregnancy failure is certain. the preparation can be used for this purpose in an ambulatory setting. the dosage and route of administration will be similar to the use of cytotec in pregnancy termination after using mifegyne. informed consent and medical surveillance are required.softening and dilation of the cervix for performing intrauterine procedures, such as: curettage, hysteroscopy, iud insertion and others, according to clinical judgment. the preparation can be used for this purpose in an ambulatory setting. the route of administration (vaginal, sublingual, buccal, oral or rectal) and the dosage are according to the decision of the attending doctor.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - teriparatide - solution for injection - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy .